SCHEMBL2111476

SCHEMBL2111476

O=[N+]([O-])c1cc(Cl)c2cccnc2c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 1.00
KDM4E B2RXH2 10/20 1.00
MEN1 O00255 9/20 1.00
KMT2A Q03164 9/20 1.00
TDP1 Q9NUW8 8/20 1.00
HTT P42858 7/20 1.00
LMNA P02545 7/20 1.00
SMN1; SMN2 Q16637 6/20 1.00
L3MBTL1 Q9Y468 6/20 1.00
PKM P14618 3/20 1.00
ALDH1A1 P00352 11/20 0.79
HSP90AA1 P07900 5/20 0.79
OPRK1 P41145 4/20 0.79
CTSB P07858 3/20 0.78
GAA P10253 3/20 0.78
IDO1 P14902 2/20 0.78
TDO2 P48775 2/20 0.78
POLB P06746 3/20 0.70
RECQL P46063 2/20 0.70
BLM P54132 2/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10521547 0.88 ALDH1A1 (1.00) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL8164006 0.88 MAPT (1.00) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL18300579 0.88 MAPT (1.00) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL24716142 0.84 KDM4E (0.72) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL7960630 0.83 MAPT (0.79) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL27190082 0.82 MAPT (1.00) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL27190087 0.82 KDM4E (0.78) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL17597346 0.82 KMT2A (0.70) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL24716103 0.82 MAPT (0.78) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL27190064 0.82 MAPT (0.78) MAPTKDM4EMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265677-B1 CORROSION DETECTION PRODUCT AND METHOD BATTELLE MEMORIAL INSTITUTE (US) 2019-05-15 EP claimed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
EP-4537825-A1 USE OF NITROXOLINE COMPOUND IN ENHANCING EFFECT OF ANTIBACTERIAL AGENT Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-04-16 EP disclosed
CN-118843464-A Application of nitrooxyquinoline compound in enhancing antibacterial agent effect 江苏亚虹医药科技股份有限公司 2024-10-25 CN disclosed
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-07-25 US disclosed
EP-4349815-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2024-04-10 EP disclosed
CN-117224542-A Application of nitrooxyquinoline compound in enhancing antibacterial agent effect 江苏亚虹医药科技股份有限公司 2023-12-15 CN disclosed
WO-2023236893-A1 USE OF NITROXOLINE COMPOUND IN ENHANCING EFFECT OF ANTIBACTERIAL AGENT 江苏亚虹医药科技股份有限公司 2023-12-14 WO disclosed
WO-2022253152-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2022-12-08 WO disclosed
WO-2020055192-A2 PREPARATION METHOD FOR QUINOLINE-5, 8-DIONE DERIVATIVE WHICH IS TGASE 2 INHIBITOR 재단법인 대구경북첨단의료산업진흥재단 2020-03-19 WO disclosed
WO-2007068316-A1 HYDROXYQUINOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2007-06-21 WO disclosed
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-05-03 US disclosed
EP-0327052-A2 Use of quinoline derivatives for making a medicament effective in the prevention and treatment of ulcers RORER INTERNATIONAL (OVERSEAS) INC. (US) 1989-08-09 EP disclosed
US-4831040-A (IMIDAZOLO-, THIAZOLO-, OXAZOLO-)(4,5-H)-QUINOLINE RORER PHARMACEUTICAL CORPORATION (US) 1989-05-16 US disclosed
EP-0090360-B1 NEW QUINOLINE AND RELATED COMPOUNDS USEFUL AS ANTI-ALLERGY AGENTS RORER INTERNATIONAL (OVERSEAS) INC. (US) 1988-05-18 EP disclosed
US-4698346-A Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents USV PHARMACEUTICAL CORPORATION (US) 1987-10-06 US disclosed
US-4656281-A Imidazo quinoline compounds useful as anti-allergy agents USV PHARMACEUTICAL CORP. (US) 1987-04-07 US disclosed
US-4563463-A ASTHMA USV PHARMACEUTICAL CORP. (US) 1986-01-07 US disclosed
US-4522947-A Certain 1,3-oxazolo[4,5H]quinolines useful as anti-allergy agents USV PHARMACEUTICAL CORPORATION (US) 1985-06-11 US disclosed
EP-0090360-A2 New quinoline and related compounds useful as anti-allergy agents RORER INTERNATIONAL (OVERSEAS) INC. (US) 1983-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain LCK, PTPN6, PTPN22 MAPT 2522/4885KDM4E 1518/4885MEN1 4192/4885
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF CYP3A7, UGT1A7, UGT2B7 MAPT 4416/4885KDM4E 2921/4885MEN1 970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.